Leiden, The Netherlands, July 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today confirmed that on July 3 (one year following the closing of its IPO), it filed a shelf registration statement with the US Securities and Exchange Commission. The filing of the registration statement is not an offering to sell securities and is intended to enable Prosensa the flexibility to raise up to $150 million in one or more offerings while the shelf registration statement is effective, if the company chooses to do so. The specific terms of any securities that the Company may offer, if it chooses to do so, will be determined at the time of such offering and will be described in a separately filed prospectus supplement at the time of such offering. The shelf registration statement also includes the shares of Prosensa’s three largest shareholders. There are no immediate plans to offer or sell securities under the shelf registration statement.
Help employers find you! Check out all the jobs and post your resume.
